146.68
Irhythm Technologies Inc stock is traded at $146.68, with a volume of 353.33K.
It is up +1.00% in the last 24 hours and up +8.51% over the past month.
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
See More
Previous Close:
$145.23
Open:
$146.85
24h Volume:
353.33K
Relative Volume:
0.75
Market Cap:
$4.49B
Revenue:
$560.03M
Net Income/Loss:
$-150.66M
P/E Ratio:
-30.18
EPS:
-4.86
Net Cash Flow:
$-87.43M
1W Performance:
+4.40%
1M Performance:
+8.51%
6M Performance:
+72.20%
1Y Performance:
+49.90%
Irhythm Technologies Inc Stock (IRTC) Company Profile
Name
Irhythm Technologies Inc
Sector
Industry
Phone
415-632-5700
Address
699 8TH STREET, San Francisco, CA
Compare IRTC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IRTC
Irhythm Technologies Inc
|
146.68 | 4.49B | 560.03M | -150.66M | -87.43M | -4.86 |
![]()
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
Irhythm Technologies Inc Stock (IRTC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-02-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Dec-03-24 | Resumed | Wells Fargo | Equal Weight |
Oct-04-24 | Initiated | Goldman | Neutral |
Jun-20-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Dec-11-23 | Upgrade | Citigroup | Neutral → Buy |
Jul-19-23 | Initiated | Robert W. Baird | Outperform |
Feb-07-23 | Initiated | Wells Fargo | Overweight |
Nov-07-22 | Upgrade | Wolfe Research | Underperform → Peer Perform |
Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
Apr-06-22 | Initiated | Wolfe Research | Underperform |
Feb-24-22 | Upgrade | Needham | Hold → Buy |
Jan-18-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-12-22 | Upgrade | BTIG Research | Neutral → Buy |
Jan-11-22 | Upgrade | Oppenheimer | Perform → Outperform |
Dec-21-21 | Resumed | Canaccord Genuity | Buy |
Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
Jun-02-21 | Downgrade | Citigroup | Buy → Neutral |
Apr-13-21 | Downgrade | BTIG Research | Buy → Neutral |
Apr-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
Feb-26-21 | Downgrade | Colliers Securities | Buy → Neutral |
Jan-29-21 | Reiterated | Needham | Hold |
Nov-17-20 | Downgrade | Oppenheimer | Outperform → Perform |
Sep-11-20 | Initiated | Needham | Hold |
Sep-02-20 | Initiated | Robert W. Baird | Neutral |
Aug-07-20 | Upgrade | Colliers Securities | Neutral → Buy |
Aug-05-20 | Upgrade | Oppenheimer | Perform → Outperform |
Mar-05-20 | Initiated | Citigroup | Buy |
Feb-06-20 | Initiated | BTIG Research | Buy |
Jan-10-20 | Initiated | William Blair | Outperform |
Jan-08-20 | Initiated | SunTrust | Buy |
Oct-22-19 | Initiated | Oppenheimer | Perform |
Feb-20-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Sep-13-18 | Reiterated | Canaccord Genuity | Buy |
Sep-06-18 | Initiated | Chardan Capital Markets | Buy |
Aug-02-18 | Upgrade | Dougherty & Company | Sell → Neutral |
Jul-16-18 | Downgrade | Dougherty & Company | Neutral → Sell |
Dec-01-17 | Initiated | Dougherty & Company | Neutral |
View All
Irhythm Technologies Inc Stock (IRTC) Latest News
Patent Office Leader Rejects IPRs Based On 12-Year Wait - Law360
iRhythm Technologies stock hits 52-week high at $147 By Investing.com - Investing.com South Africa
iRhythm Technologies stock hits 52-week high at $147 - Investing.com India
Should You Hold iRhythm Technologies (IRTC)? - Insider Monkey
iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
U.S. Smart Wearable ECG Monitors Market Size Report 2030 - Grand View Research
Q1 Patient Monitoring Earnings: Insulet (NASDAQ:PODD) Earns Top Marks - Yahoo Finance
iRhythm at 45th Annual William Blair Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Heart Device Maker iRhythm Gets Investor Claims Trimmed - Law360
Global AI in Remote Patient Monitoring Market to Cross USD 13 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
iRhythm Fails to Snuff Investor Suit Over Heart Monitor Flaws - Bloomberg Law News
Healthcare Tech And Innovation: Heart Monitors Improving - Seeking Alpha
iRhythm Technologies Inc (IRTC) Stock Price Up 3.75% on Jun 3 - GuruFocus
Shareholders that lost money on iRhythm Technologies, Inc.(IRTC) should contact Levi & Korsinsky about pending Class ActionIRTC - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Smart Wearable ECG Monitors Market Size Report, 2030 - Grand View Research
INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of iRhythm Technologies, Inc. (IRTC) - ACCESS Newswire
(IRTC) Trading Signals - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Encourages iRhythm Technologies, Inc. (IRTC) Investors to Inquire about Securities Investigation - ACCESS Newswire
iRhythm Technologies Holds 2025 Annual Stockholders Meeting - TipRanks
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Reach Out - ACCESS Newswire
iRhythm Technologies, Inc. (NASDAQ:IRTC) Shares Sold by Nuveen Asset Management LLC - Defense World
Millennium Management LLC Reduces Stake in iRhythm Technologies, Inc. (NASDAQ:IRTC) - Defense World
BNP Paribas Financial Markets Sells 7,391 Shares of iRhythm Technologies, Inc. (NASDAQ:IRTC) - Defense World
(IRTC) Technical Data - news.stocktradersdaily.com
PRE Soars Over 70% In Just Three Days, VIGL Snapped Up, IRTC Finds Its Rhythm Again... - Nasdaq
Ameriprise Financial Inc. Buys 8,528 Shares of iRhythm Technologies, Inc. (NASDAQ:IRTC) - Defense World
Demystifying iRhythm Technologies: Insights From 6 Analyst Reviews - Benzinga
iRhythm Technologies (IRTC) Sees Price Target Hiked by Citigroup - GuruFocus
iRhythm Technologies (IRTC) Sees Price Target Hiked by Citigroup | IRTC Stock News - GuruFocus
iRhythm (IRTC) Price Target Lifted by Citi Analyst to $167 | IRT - GuruFocus
iRhythm Technologies to Participate in Upcoming Investor Conferences - The Manila Times
iRhythm Technologies to Participate in Upcoming Investor Conferences | IRTC Stock News - GuruFocus
iRhythm Technologies, Inc. to Present at Multiple Investor Conferences in June 2025 - Nasdaq
iRhythm Stock Hits 52-Week High at $142.69 Amid Growth Surge - Investing.com Australia
IRTC SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds iRhythm Technologies, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Brokerages Set iRhythm Technologies, Inc. (NASDAQ:IRTC) PT at $128.55 - MarketBeat
3 Overrated Stocks Facing Headwinds - Yahoo Finance
iRhythm Technologies, Inc. (NASDAQ:IRTC) Given Average Rating of “Moderate Buy” by Analysts - Defense World
IRTC Q1 Earnings Call: Outperformance Driven by Zio AT and Primary Care Channel Expansion - Yahoo Finance
After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order? - TradingView
Cardiac Event Monitor Market Expanding Due to Rising Cardiac - openPR.com
iRhythm Technologies, Inc. (NASDAQ:IRTC): Is Breakeven Near? - simplywall.st
2 Healthcare Stocks to Keep an Eye On and 1 to Ignore - Yahoo Finance
Transcript : IRhythm Technologies, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
iRhythm at Bank of America Conference: Strategic Growth and Challenges By Investing.com - Investing.com India
iRhythm at Bank of America Conference: Strategic Growth and Challenges - Investing.com
Why iRhythm Technologies (IRTC) Is Among the Best Performing Healthcare Stocks to Buy Now - Insider Monkey
UPCOMING IRTC DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds iRhythm Technologies, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
11 Best Performing Healthcare Stocks to Buy Now - Insider Monkey
iRhythm Technologies, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 8, 2024 to Discuss Your Rights – IRTC - ACCESS Newswire
Irhythm Technologies Inc Stock (IRTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Irhythm Technologies Inc Stock (IRTC) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Rosenbaum Marc W. | Chief Accounting Officer |
Jun 02 '25 |
Sale |
140.21 |
696 |
97,586 |
11,105 |
Wilson Daniel G. | Chief Financial Officer |
May 02 '25 |
Sale |
125.00 |
2,000 |
250,000 |
43,307 |
Patterson Chad | Chief Commercial Officer |
May 02 '25 |
Sale |
120.55 |
8,510 |
1,025,898 |
49,930 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):